Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials

JAMA Intern Med. 2019 May 1;179(5):721-722. doi: 10.1001/jamainternmed.2018.8019.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cohort Studies
  • Communication*
  • Research Design*